Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study

Michael Schiff; Bernard Combe; Thomas Dörner; Joel M Kremer; Thomas W Huizinga; Melissa Veenhuizen; Anne Gill; Wendy Komocsar; Pierre-Yves Berclaz; Robert Ortmann; Chin Lee

doi:10.1136/rmdopen-2014-000037

Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study

RMD Open ◽

10.1136/rmdopen-2014-000037 ◽

2015 ◽

Vol 1 (1) ◽

pp. e000037 ◽

Cited By ~ 12

Author(s):

Michael Schiff ◽

Bernard Combe ◽

Thomas Dörner ◽

Joel M Kremer ◽

Thomas W Huizinga ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Tnf Inhibitors ◽

Inadequate Response ◽

Efficacy And Safety ◽

Severe Rheumatoid Arthritis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double-Blind, Placebo/Active-Controlled, Dose-Ra

Arthritis & Rheumatology ◽

10.1002/art.39249 ◽

2015 ◽

Vol 67 (10) ◽

pp. 2591-2600 ◽

Cited By ~ 47

Author(s):

Michael E. Weinblatt ◽

Philip Mease ◽

Eduardo Mysler ◽

Tsutomu Takeuchi ◽

Edit Drescher ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Inadequate Response ◽

Efficacy And Safety ◽

Severe Rheumatoid Arthritis ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

AB0438 Efficacy and Safety of Tabalumab, an Anti-B Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis WHO HAD an Inadequate Response to Tnf-Alpha Inhibitors: Results from A Phase 3 Multicenter, Randomized, Double-Blind Study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2014-eular.3305 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 952.3-953

Author(s):

M. Schiff ◽

B. Combe ◽

T. Dörner ◽

J.M. Kremer ◽

T.W. Huizinga ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

B Cell ◽

Tnf Alpha ◽

Double Blind Study ◽

Inadequate Response ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

B Cell Activating Factor

Download Full-text

Results of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Sirukumab, An Anti-IL-6 Cytokine Monoclonal Antibody, In Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment (Sirround-D)

Value in Health ◽

10.1016/j.jval.2016.09.1074 ◽

2016 ◽

Vol 19 (7) ◽

pp. A531 ◽

Cited By ~ 2

Author(s):

T Takeuchi ◽

C Thorne ◽

G Karpouzas ◽

S Sheng ◽

W Xu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Rheumatic Drug

Download Full-text

Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3523879 ◽

2020 ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Inadequate Response ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double‐blind, Placebo‐controlled Phase 2 study

Arthritis & Rheumatology ◽

10.1002/art.41555 ◽

2020 ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Inadequate Response ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

FRI0326 Efficacy and Safety of Tabalumab, an Anti-B Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis Who HAD an Inadequate Response to Methotrexate Therapy: Results from A Phase 3 Multicenter, Randomized, Double-Blind Study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2014-eular.1535 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 504.2-504

Author(s):

J.S. Smolen ◽

M.E. Weinblatt ◽

D. van der Heijde ◽

W.F. Rigby ◽

R. van Vollenhoven ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

B Cell ◽

Methotrexate Therapy ◽

Double Blind Study ◽

Inadequate Response ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

B Cell Activating Factor

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727328077.793564275 ◽

2019 ◽

Author(s):

Ladislav Senolt

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group

Download Full-text

OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial

10.1136/annrheumdis-2017-eular.2443 ◽

2017 ◽

Cited By ~ 3

Author(s):

DD Gladman ◽

WFC Rigby ◽

VF Azevedo ◽

F Behrens ◽

R Blanco ◽

...

Keyword(s):

Tumour Necrosis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Inadequate Response ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Necrosis Factor

Download Full-text

OP0234 EFFICACY AND SAFETY OF BRODALUMAB, AN ANTI-INTERLEUKIN-17 RECEPTOR A MONOCLONAL ANTIBODY, IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A 16 WEEK RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

10.1136/annrheumdis-2019-eular.6888 ◽

2019 ◽

Cited By ~ 2

Author(s):

James Cheng-Chung Wei ◽

Tae-Hwan Kim ◽

Mitsumasa Kishimoto ◽

Takuya Morishige ◽

Naoki Ogusu ◽

...

Keyword(s):

Monoclonal Antibody ◽

Axial Spondyloarthritis ◽

Controlled Study ◽

Interleukin 17 ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

Arthritis & Rheumatism ◽

10.1002/art.27524 ◽

2010 ◽

Vol 62 (8) ◽

pp. 2227-2238 ◽

Cited By ~ 69

Author(s):

Mikkel Østergaard ◽

Bo Baslund ◽

William Rigby ◽

Bernadette Rojkovich ◽

Christian Jorgensen ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Phase I ◽

Inadequate Response ◽

Disease Modifying Antirheumatic Drugs ◽

Antirheumatic Drugs ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Anti Cd20

Download Full-text